Agency
State of New Mexico
State of New Mexico was paid $15.87M by Medicaid between Jan 2018 and Jun 2024, across 135 billing codes. Its largest line is U0002, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc — 12% of everything it billed.
33Billing provider infoSTATE OF NEW MEXICO
SANTA FE, NM 87505
SANTA FE, NM 87505
33aNPI1134257249assigned 03/01/2007
33bProvider typePublic Health or Welfare Agency
28Total paid$15.87M
24GClaims539,697
24DCodes billed135
24AFirst – last monthJan 2018 – Jun 2024
Compared with peers
Next to other Public Health or Welfare Agency providers in New Mexico
Rank by total paid#1 of 6
Median peer was paid$198K
This provider vs. median80×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,205 | $1.69M | |
| 2019 | 72,878 | $2.04M | |
| 2020 | 180,765 | $5.50M | |
| 2021 | 79,420 | $2.40M | |
| 2022 | 55,869 | $1.44M | |
| 2023 | 57,768 | $1.74M | |
| 2024incomplete | 28,792 | $1.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 12% | 42,023 | 35,336 | $1.94M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 12% | 27,068 | 22,574 | $1.91M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 12% | 82,315 | 71,960 | $1.85M |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 7.4% | 35,642 | 33,257 | $1.17M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 6.9% | 53,143 | 52,401 | $1.09M |
| 90472 | Immunization administration, each additional vaccine (list separately) | 5.3% | 21,470 | 20,595 | $834K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 5.1% | 902 | 894 | $807K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 4.7% | 8,399 | 8,274 | $740K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.7% | 32,490 | 25,348 | $592K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.5% | 15,504 | 13,689 | $563K |
| S4993 | Contraceptive pills for birth control | 3.2% | 6,001 | 5,659 | $508K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.0% | 7,470 | 7,039 | $478K |
123 more codes
| 99203 | Doctor's office visit, new patient (routine) | 2.2% | 3,619 | $354K |
| 0002A | 1.4% | 6,295 | $226K | |
| 0001A | 1.2% | 5,878 | $197K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.1% | 7,818 | $179K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.1% | 2,679 | $174K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,286 | $133K |
| 90632 | <1% | 3,036 | $123K | |
| 0003A | <1% | 4,052 | $119K | |
| 81025 | <1% | 13,586 | $113K | |
| 90651 | <1% | 7,165 | $100K | |
| 90686 | <1% | 19,517 | $99K | |
| 90716 | <1% | 3,270 | $94K | |
| 86780 | <1% | 6,374 | $90K | |
| 11981 | <1% | 425 | $81K | |
| 86703 | <1% | 5,571 | $77K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,687 | $71K |
| 90739 | <1% | 484 | $67K | |
| 87538 | <1% | 1,778 | $61K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,564 | $58K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,592 | $56K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,563 | $56K |
| 80305 | <1% | 4,297 | $52K | |
| 86593 | <1% | 11,759 | $49K | |
| 88142 | <1% | 2,465 | $48K | |
| 90715 | <1% | 8,369 | $44K | |
| 0124A | <1% | 1,079 | $38K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,384 | $36K |
| 90707 | <1% | 2,015 | $35K | |
| 0012A | <1% | 985 | $35K | |
| 0011A | <1% | 1,066 | $34K | |
| 86803 | <1% | 1,741 | $27K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 128 | $24K |
| 90710 | <1% | 2,987 | $23K | |
| 87210 | <1% | 4,371 | $23K | |
| 91322 | <1% | 320 | $20K | |
| 99201 | <1% | 706 | $19K | |
| 0031A | <1% | 562 | $19K | |
| 81001 | <1% | 4,633 | $17K | |
| 0071A | <1% | 455 | $17K | |
| 0072A | <1% | 391 | $15K | |
| 90480 | <1% | 525 | $14K | |
| 11982 | <1% | 81 | $14K | |
| 0013A | <1% | 483 | $14K | |
| 90746 | <1% | 172 | $13K | |
| 86704 | <1% | 1,034 | $12K | |
| 86480 | <1% | 205 | $12K | |
| 86705 | <1% | 1,034 | $12K | |
| 86706 | <1% | 1,053 | $11K | |
| 0051A | <1% | 312 | $10K | |
| 87340 | <1% | 1,002 | $10K | |
| 87536 | <1% | 116 | $9K | |
| 91320 | <1% | 97 | $8K | |
| 90473 | <1% | 357 | $7K | |
| 90670 | <1% | 1,761 | $7K | |
| 80053 | Comprehensive metabolic panel | <1% | 689 | $7K |
| A4267 | Contraceptive supply, condom, male, each | <1% | 1,635 | $7K |
| 90619 | <1% | 2,804 | $7K | |
| 87562 | <1% | 186 | $7K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 64 | $6K |
| 90713 | <1% | 1,409 | $5K | |
| J7303 | Contraceptive supply, hormone containing vaginal ring, each | <1% | 42 | $5K |
| 90636 | <1% | 42 | $5K | |
| 0154A | <1% | 121 | $5K | |
| 0134A | <1% | 140 | $5K | |
| 90714 | <1% | 254 | $4K | |
| 0073A | <1% | 115 | $4K | |
| 99442 | <1% | 41 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 493 | $4K |
| 90633 | <1% | 4,286 | $4K | |
| 90734 | <1% | 5,654 | $4K | |
| 87806 | <1% | 120 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 82 | $3K |
| 90696 | <1% | 1,992 | $3K | |
| 81002 | <1% | 1,103 | $3K | |
| 98968 | <1% | 73 | $2K | |
| 87480 | <1% | 99 | $2K | |
| 87205 | <1% | 469 | $2K | |
| 87510 | <1% | 99 | $2K | |
| 91321 | <1% | 142 | $2K | |
| 0081A | <1% | 51 | $2K | |
| 87660 | <1% | 96 | $2K | |
| 0053A | <1% | 44 | $2K | |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | <1% | 1,059 | $2K |
| 99441 | <1% | 30 | $2K | |
| 99423 | <1% | 16 | $2K | |
| 90671 | <1% | 35 | $1K | |
| 91319 | <1% | 28 | $1K | |
| 91318 | <1% | 27 | $941.39 | |
| 90744 | <1% | 1,142 | $833.12 | |
| 90700 | <1% | 636 | $675.38 | |
| Q3014 | Telehealth originating site facility fee | <1% | 27 | $561.75 |
| 0052A | <1% | 14 | $560.00 | |
| 87535 | <1% | 769 | $505.32 | |
| 0083A | <1% | 12 | $480.00 | |
| 90698 | <1% | 465 | $362.15 | |
| 98966 | <1% | 25 | $299.06 | |
| 90677 | <1% | 297 | $291.57 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29 | $253.97 |
| 90680 | <1% | 339 | $252.78 | |
| 90620 | <1% | 45 | $177.74 | |
| 90674 | <1% | 7,811 | $123.13 | |
| 83986 | <1% | 31 | $110.67 | |
| 90723 | <1% | 476 | $95.01 | |
| 85660 | <1% | 12 | $71.94 | |
| 82120 | <1% | 14 | $71.68 | |
| 90672 | <1% | 292 | $54.08 | |
| 90756 | <1% | 108 | $53.32 | |
| 91307 | <1% | 207 | $40.00 | |
| 90648 | <1% | 158 | $24.65 | |
| 90688 | <1% | 694 | $1.91 | |
| 90649 | <1% | 136 | $1.23 | |
| 90647 | <1% | 116 | $0.87 | |
| 90697 | <1% | 67 | $0.28 | |
| 90685 | <1% | 12 | $0.07 | |
| 90621 | <1% | 13 | $0.01 | |
| 91305 | 0% | 280 | $0.00 | |
| 91301 | 0% | 972 | $0.00 | |
| 91303 | 0% | 150 | $0.00 | |
| 91300 | 0% | 920 | $0.00 | |
| 91312 | 0% | 163 | $0.00 | |
| 99001 | 0% | 35 | $0.00 | |
| 99071 | 0% | 66 | $0.00 | |
| 91313 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARTINEZ, SANDRA (DEPUTY DIRECTOR, FINANCE AND ADMINI)
| Provider | Location | Paid |
|---|---|---|
| State of New Mexico | Santa Fe, NM | $17K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.